{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:40:26Z","timestamp":1789832426776,"version":"4.0.1"},"reference-count":38,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,7,26]]},"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Impaired glucose tolerance (IGT) is highly prevalent after stroke and is associated with recurrent stroke and unfavourable outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aimed to assess the feasibility, safety and effects on glucose metabolism of metformin or sitagliptin in patients with transient ischaemic attack (TIA) or minor ischaemic stroke and IGT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We performed a multicentre, randomised, controlled, open-label phase II trial with blinded outcome assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Patients were randomised in a 2:1:1 ratio to \u2018no medication\u2019, sitagliptin or metformin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Primary outcome measures were baseline adjusted differences of 2-hour postload glucose; secondary outcome measures fasting glucose, glycosylated haemoglobin 1c (HbA1c) levels, tolerability and safety of metformin and sitagliptin at 6 months. Patients on metformin or sitagliptin were contacted by telephone for recording of possible adverse events and to support continuation of treatment at 2 weeks, 6 weeks and 3 months after inclusion. These events were not analysed as outcome measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-three patients were randomised to control group, 26 to metformin and 22 to sitagliptin. We found no significant differences in 2-hour postload glucose between patients on antidiabetic drugs and controls ((\u22120.04\u2009mmol\/L (95%\u2009CI \u22120.53 to 0.45)). Patients in the treatment arms had reduced fasting glucose: ((\u22120.21\u2009mmol\/L (95%\u2009CI \u22120.36 to \u22120.06)) and HbA1c levels ((\u22121.16\u2009mmol\/mol (95%\u2009CI \u22121.84 to \u22120.49)). Thirteen patients (50%) on metformin and 7 (32%) on sitagliptin experienced side effects. Sixteen patients (61%) in the metformin and 13 (59%) in the sitagliptin group were still on treatment after 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Metformin and sitagliptin were both effective in reducing fasting glucose and HbA1c levels in patients with recent TIA or minor ischaemic stroke and IGT. However, the reduction of glucose levels and sample size was relatively small. The clinical relevance, therefore, needs to be tempered. A phase III trial is needed to investigate whether medical treatment, compared with lifestyle intervention or a combination of both, not only improves glucose metabolism in IGT, but also leads to reduction of recurrent TIA or ischaemic stroke in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>NL3048.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-046113","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T12:56:02Z","timestamp":1631796962000},"page":"e046113","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9405-0583","authenticated-orcid":false,"given":"Elizabeth","family":"Osei","sequence":"first","affiliation":[{"name":"Neurology, Flevoziekenhuis, Almere, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Zandbergen","sequence":"additional","affiliation":[{"name":"Internal Medicine, Erasmus MC, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J A M","family":"Brouwers","sequence":"additional","affiliation":[{"name":"Neurology, Medisch Spectrum Twente, Enschede, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laus J M M","family":"Mulder","sequence":"additional","affiliation":[{"name":"Neurology, Ikazia Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Koudstaal","sequence":"additional","affiliation":[{"name":"Neurology, Erasmus MC, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester","family":"Lingsma","sequence":"additional","affiliation":[{"name":"Public Health, Erasmus MC, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9234-3515","authenticated-orcid":false,"given":"Diederik W J","family":"Dippel","sequence":"additional","affiliation":[{"name":"Neurology, Erasmus MC, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen","family":"den Hertog","sequence":"additional","affiliation":[{"name":"Neurology, Isala Hospitals, Zwolle, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"2025121402575463000_11.9.e046113.1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcq062"},{"key":"2025121402575463000_11.9.e046113.2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.294792"},{"key":"2025121402575463000_11.9.e046113.3","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.2.227"},{"key":"2025121402575463000_11.9.e046113.4","doi-asserted-by":"publisher","DOI":"10.1159\/000360810"},{"key":"2025121402575463000_11.9.e046113.5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1179\/016164110X12656393665242","article-title":"Persistence and predictors of abnormal glucose metabolisms in patients after acute stroke","volume":"32","author":"Jia","year":"2010","journal-title":"Neurol Res"},{"key":"2025121402575463000_11.9.e046113.6","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hci134"},{"key":"2025121402575463000_11.9.e046113.7","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.01.012","article-title":"Occurrence and predictors of persistent impaired glucose tolerance after acute ischemic stroke or transient ischemic attack","volume":"23","author":"Fonville","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2025121402575463000_11.9.e046113.8","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000221766.73692.0b"},{"key":"2025121402575463000_11.9.e046113.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3564"},{"key":"2025121402575463000_11.9.e046113.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2007.10.007"},{"key":"2025121402575463000_11.9.e046113.11","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.113.002977"},{"key":"2025121402575463000_11.9.e046113.12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118709"},{"key":"2025121402575463000_11.9.e046113.13","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(93)90005-9"},{"key":"2025121402575463000_11.9.e046113.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-2977(97)00012-0"},{"key":"2025121402575463000_11.9.e046113.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3759-5"},{"key":"2025121402575463000_11.9.e046113.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506930"},{"key":"2025121402575463000_11.9.e046113.17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1177\/1741826711421687","article-title":"Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials","volume":"18","author":"Hopper","year":"2011","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2025121402575463000_11.9.e046113.18","doi-asserted-by":"publisher","DOI":"10.1111\/ijs.12023"},{"key":"2025121402575463000_11.9.e046113.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01334.x"},{"key":"2025121402575463000_11.9.e046113.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01187.x"},{"key":"2025121402575463000_11.9.e046113.21","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025121402575463000_11.9.e046113.22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021887"},{"key":"2025121402575463000_11.9.e046113.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39063.689375.55"},{"key":"2025121402575463000_11.9.e046113.24","first-page":"393","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2006","journal-title":"N Engl J Med"},{"key":"2025121402575463000_11.9.e046113.25","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-16-1"},{"key":"2025121402575463000_11.9.e046113.26","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.19.5.604"},{"key":"2025121402575463000_11.9.e046113.27","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-S006"},{"key":"2025121402575463000_11.9.e046113.28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications: report of a who consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Geneva. Diabet Med"},{"key":"2025121402575463000_11.9.e046113.29","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.019582"},{"key":"2025121402575463000_11.9.e046113.30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-1-1"},{"key":"2025121402575463000_11.9.e046113.31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/000456329803500107","article-title":"The reproducibility and usefulness of the oral glucose tolerance test in screening for diabetes and other cardiovascular risk factors","volume":"35 (Pt 1","author":"Ko","year":"1998","journal-title":"Ann Clin Biochem"},{"key":"2025121402575463000_11.9.e046113.32","first-page":"1","article-title":"Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus \u2014 the randomised, blinded Copenhagen insulin and metformin therapy (CIMT) trial","volume":"6","author":"Lundby-Christensen","year":"2015","journal-title":"BMJ Open"},{"key":"2025121402575463000_11.9.e046113.33","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/jcph.1431","article-title":"Effects of sitagliptin on lipid profile in patients with type 2 diabetes mellitus after 7 years of therapy","volume":"59","author":"Derosa","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"2025121402575463000_11.9.e046113.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352"},{"key":"2025121402575463000_11.9.e046113.35","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0656"},{"key":"2025121402575463000_11.9.e046113.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806802"},{"key":"2025121402575463000_11.9.e046113.37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3390\/ijerph16020196","article-title":"Adherence to treatment in stroke patients","volume":"16","author":"Cheiloudaki","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"2025121402575463000_11.9.e046113.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61457-4"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-046113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T10:58:05Z","timestamp":1765709885000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-046113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,16]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/bmjopen-2020-046113"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-046113","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}